Target intelligence / Profile preview

Immunoglobulin lambda variable 3-30 (IGLV3-30)

Target
IGLV3-30
Molecular classification
Immunoglobulin variable region, Immunoglobulin light chain (lambda type), Other
01

Overview

Immunoglobulin lambda variable 3-30 (IGLV3-30) is a gene that encodes the variable region of the lambda light chain in human antibodies. Immunoglobulin variable regions create the diversity of binding sites necessary for antibody-mediated recognition of foreign antigens. The IGLV3-30 gene is part of the immunoglobulin lambda (IGL) locus on chromosome 22 and contributes to the repertoire of antibody specificities via V-J recombination and somatic hypermutation. It does not function as a classical drug target such as a receptor, enzyme, or transporter, but forms part of secreted or membrane-bound immunoglobulins expressed by B-cells in the adaptive immune system. While immunoglobulin light chains—including lambda types—can be overexpressed in certain hematological malignancies (e.g., multiple myeloma), IGLV3-30 itself is not a direct therapeutic target and is not specifically associated with targeted drugs or therapies. If you need further detail on the broader immunoglobulin light chain family, or associated pathologies, or wish for information on the functional antibody molecule as a drug target (e.g., CD20 receptor or immunoglobulin Fc regions), clarification can be provided.

Other names
IGLV3-30Immunoglobulin lambda variable region 3-30Ig lambda V3-30
02

Mechanism of action

Not applicable; not a direct therapeutic target. The variable region is involved in antigen recognition as part of antibody molecules.

03

Biological functions

Antigen bindingImmune responseAntibody diversity (via V(D)J recombination and somatic hypermutation)
04

Disease associations

Cancer (as component in tumor-derived immunoglobulins)Other (role in infection, humoral immunity via antibodies; not specific to one disease)May be involved in lymphoid neoplasms if aberrantly expressed
05

Safety considerations

None specific. General concerns apply to antibodies (e.g., immune complex diseases, autoimmune reactions) but not to this variable region in isolation.
06

Interacting drugs

None known; no approved drugs specifically target this variable region—antibodies as a class may be targeted, not specific lambda V region
07

Biomarkers

Immunoglobulin light chain usage (lambda/kappa ratio) can serve as a diagnostic marker in certain blood cancers (e.g., multiple myeloma), but not specific to IGLV3-30Not used as a standalone biomarker

Beyond the preview

Go deeper on Immunoglobulin lambda variable 3-30 (IGLV3-30).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin lambda variable 3-30 (IGLV3-30).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call